Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) announced on July 30, 2026, that its subsidiaries have signed a Memorandum of Agreement with Invitrx Therapeutics Inc. to explore two key initiatives: manufacturing and selling GENREVER cosmetic products in the United States and supplying materials for regenerative medicine projects in Indonesia. The collaboration builds on a six-year commercial relationship, aiming to expand Instinct Bio's international footprint.
Under the proposed framework, Instinct Bio will license the GENREVER trademark, while its subsidiary Artisans Production will provide proprietary formulations and raw materials. INVITRX is expected to manufacture the products at its U.S. GMP facility, positioning GENREVER as a premium Japanese cosmetics brand for the American market, subject to regulatory approvals. This move could strengthen Instinct Bio's presence in the competitive U.S. cosmetics sector, leveraging INVITRX's manufacturing capabilities to ensure quality and compliance.
Separately, the parties intend to collaborate on Indonesia's emerging regenerative medicine ecosystem. INVITRX may supply concentrated exosomes and conditioned media for proposed clinics and an in-hospital cell processing center. This initiative aligns with Indonesia's growing healthcare demand and could establish a localized platform for advanced therapies. The collaboration underscores the potential for cross-border partnerships to address unmet medical needs in rapidly developing markets.
Tomoki Nagano, CEO of Instinct Bio, emphasized the strategic importance of the collaboration, noting that combining the GENREVER brand, proprietary formulations, and INVITRX's manufacturing expertise creates a foundation for growth in the U.S. and Southeast Asia. The companies will now negotiate definitive agreements while progressing regulatory assessments. Success could enhance Instinct Bio's portfolio and revenue streams, while INVITRX gains access to new product lines and markets.
For more details, visit Instinct Bio's website at https://instinct-biot.com/ or view the original release on NewMediaWire.
Forward-looking statements in the release caution that definitive agreements are not guaranteed, and outcomes depend on regulatory approvals and market acceptance. However, the collaboration represents a significant step for Instinct Bio's international expansion strategy, potentially driving long-term value for shareholders and advancing regenerative medicine access in Indonesia.
